PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. [electronic resource]
Producer: 20191125Description: 2085-2091 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents, Immunological -- therapeutic use
- B7-H1 Antigen -- antagonists & inhibitors
- Biomarkers, Tumor -- genetics
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cohort Studies
- Exons -- genetics
- Female
- Follow-Up Studies
- High-Throughput Nucleotide Sequencing
- Humans
- Immunotherapy -- methods
- Lung Neoplasms -- drug therapy
- Male
- Middle Aged
- Mutation
- Prognosis
- Proto-Oncogene Proteins c-met -- genetics
- Survival Rate
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.